Reports Q4 revenue $1.29B, consensus $1.17B. “Argenx (ARGX) delivered another standout year of execution in 2025,” said Tim Van Hauwermeiren, CEO of Argenx. “We reached 19,000 patients globally with VYVGART, expanded our impact across gMG and CIDP through the successful launch of the pre-filled syringe, and made substantial progress across our development programs, advancing the pipeline towards key milestones.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx (ARGX) Q4 Earnings Cheat Sheet
- Argenx price target raised to $1,317 from $1,264 at Wells Fargo
- argenx Wins FDA Priority Review for VYVGART in Seronegative gMG
- Argenx: Strong Vyvgart Execution, Deep Pipeline, and Vision 2030 Drive Compelling Buy-Rated Upside
- Argenx announces FDA acceptance of Vyvgart sBLA for priority review